专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2007039189A1 PHOSPHORYLATED OR NON-PHOSPHORYLATED MPR AS DIAGNOSTIC MARKER OR THERAPEUTIC TARGET 审中-公开
标题翻译：磷酸化或非磷酸化MPR作为诊断标记或治疗目标
公开(公告)号：WO2007039189A1
公开(公告)日：2007-04-12
申请号：PCT/EP2006/009351
申请日：2006-09-26
申请人： PROTEOSYS AG , CAHILL, Michael , SCHRATTENHOLZ, André , KUREK, Raffael , WALLWIENER, Diethelm , NEUBAUER, Hans , CLARE, Susan
发明人： CAHILL, Michael , SCHRATTENHOLZ, André , KUREK, Raffael , WALLWIENER, Diethelm , NEUBAUER, Hans , CLARE, Susan
IPC分类号： G01N33/574 , C07K14/72
CPC分类号： G01N33/743 , C07K14/721 , G01N33/564 , G01N33/57407 , G01N33/57415 , G01N33/57434 , G01N33/57484 , G01N33/6893 , G01N2333/723 , G01N2500/00 , G01N2800/12 , G01N2800/28 , G01N2800/367
摘要： The invention relates to the use of phosphorylated and/or non- phosphorylated membrane associated progesterone receptor component 1 (mPR or PGRMC 1 ) or progesterone membrane component 2 (PGRMC2), in particular of at least one isoform thereof, and to other proteins, in particular isoforms thereof, as diagnostic markers and/or therapeutic targets for diseases associated with aberrant biological phenotypes, reagents for influencing mPR and/or the abundance and/or activity of said other proteins and to the use of an appropriate assay.
摘要翻译：本发明涉及磷酸化和/或非磷酸化的膜相关孕激素受体组分1（mPR或PGRMC1）或孕酮酮组分2（PGRMC2），特别是其至少一种同种型和其它蛋白质在作为与异常生物表型相关的疾病的诊断标志物和/或治疗靶标，影响mPR的试剂和/或所述其它蛋白质的丰度和/或活性以及使用适当的测定法的特异性同种型。

2. 发明申请

WO2006029836A2 BREAST CANCER PROTEINS 审中-公开
标题翻译：乳腺癌蛋白
公开(公告)号：WO2006029836A2
公开(公告)日：2006-03-23
申请号：PCT/EP2005/009871
申请日：2005-09-14
申请人： PROTEOSYS AG , CAHILL, Michael , SCHRATTENHOLZ, André , KUREK, Raffael , WALLWIENER, Diethelm , NEUBAUER, Hans , CLARE, Susan
发明人： CAHILL, Michael , SCHRATTENHOLZ, André , KUREK, Raffael , WALLWIENER, Diethelm , NEUBAUER, Hans , CLARE, Susan
IPC分类号： G01N33/68
CPC分类号： G01N33/57415
摘要： The present invention relates to a pooling method for performing proteomics with human samples, preferably derived from microdissected human samples, wherein the samples are grouped into two or more pools and each pool reveals at least one protein that is differentially manifest between these pools but common to a member of a given pool. Besides, the invention refers to proteins whose abundances are upregulated in cancer cells, especially in breast cancer cells, preferably in breast cancer cells that are positive or negative towards hormone binding receptors.
摘要翻译：本发明涉及一种用人类样品进行蛋白质组学的池化方法，所述人类样品优选地源自显微解剖的人类样品，其中样品被分组为两个或更多个池，并且每个池展示至少一种这些池之间差异明显，但是对于给定池中的成员通用。此外，本发明涉及其丰度在癌细胞中上调的蛋白质，尤其是在乳腺癌细胞中，优选在对激素结合受体为阳性或阴性的乳腺癌细胞中。

3. 发明申请

WO2008037449A2 USE OF AT LEAST ONE ISOFORM OF PROGESTERONE RECEPTOR MEMBRANE COMPONENT 1 (PGRMC1) 审中-公开
标题翻译：使用前列腺素受体膜组分1（PGRMC1）的至少一种
公开(公告)号：WO2008037449A2
公开(公告)日：2008-04-03
申请号：PCT/EP2007/008370
申请日：2007-09-26
申请人： PROTEOSYS AG , CAHILL, Michael , NEUBAUER, Hans
发明人： CAHILL, Michael , NEUBAUER, Hans
IPC分类号： G01N33/574 , A61K38/00
CPC分类号： A61K38/1796 , A61K38/00 , C07K14/721 , G01N33/57415 , G01N33/57434 , G01N33/57492 , G01N33/6893 , G01N33/6896 , G01N33/74 , G01N2333/723 , G01N2800/102 , G01N2800/12 , G01N2800/24 , G01N2800/28 , G01N2800/2814 , G01N2800/32 , G01N2800/323 , G01N2800/367
摘要： The invention relates to the use of at least one isoform of progesterone receptor membrane component 1 (PGRMC1 ) as diagnostic marker and/or therapeutic target for diseases associated with neogenin and/or DCC and/or for the manufacture of a medicament for treatment of diseases associated with neogenin and/or DCC, the use of at least one reagent that influences the function of at least one isoform of PGRMC1 for the manufacture of a medicament for treatment of diseases associated with neogenin and/or DCC, the use of at least one isoform of PGRMC1 for influencing abundance or subcellular localisation of at least one class of molecules interacting with PGRMC1, an assay kit for diagnosis and/or therapy of diseases associated with neogenin and/or DCC, comprising at least one isoform of PGRMC1 and/or at least one reagent that influences the function of at least one isoform of PGRMC1, the use of at least one isoform of PGRMC1 as diagnostic marker in diagnosis for diseases associated with aberrant biological phenotypes, wherein the phosphorylation status of the at least one isoform of PGRMC1 is determined/and or estimated and the use of at least one reagent for influencing the abundance and/or activity of isoforms of proteins for diagnosis and/or therapy of diseases associated with aberrant biological phenotypes, wherein said proteins are involved in protein interaction or multiprotein complexes with either at least one isoform of phosphorylated or non-phosphorylated PGRMC1.
摘要翻译：本发明涉及孕酮受体膜组分1（PGRMC1）的至少一种同种型作为与新生血管和/或DCC相关疾病和/或用于制备用于治疗疾病的药物的诊断标记和/或治疗靶标的用途与新生血管和/或DCC相关的至少一种试剂，使用至少一种影响至少一种PGRMC1同种型的功能的试剂，用于制备用于治疗与新生血管和/或DCC相关的疾病的药物，使用至少一种用于影响与PGRMC1相互作用的至少一类分子的丰度或亚细胞定位的PGRMC1的同种型，用于诊断和/或治疗与新生血管和/或DCC相关的疾病的测定试剂盒，其包含至少一种PGRMC1的同种型和/或至少一种影响PGRMC1至少一种同种型功能的试剂，使用至少一种PGRMC1同种型作为诊断与异常相关疾病的诊断标记蚂蚁生物表型，其中PGRMC1的至少一种同种型的磷酸化状态被确定和/或估计，并且使用至少一种试剂来影响蛋白质同种型的丰度和/或活性以诊断和/或治疗疾病与异常生物表型相关，其中所述蛋白质参与与至少一种磷酸化或非磷酸化PGRMC1同种型的蛋白质相互作用或多蛋白复合物。

4. 发明申请

WO2009015799A2 NACHWEIS DER PLATINRESISTENZ 审中-公开
标题翻译：铂抗性证明
公开(公告)号：WO2009015799A2
公开(公告)日：2009-02-05
申请号：PCT/EP2008/005965
申请日：2008-07-21
申请人： EBERHARD-KARLS-UNIVERSITÄT TÜBINGEN , BONIN, Michael , HOFFMANN, Jessica , WALTER, Michael , RIESS, Olaf , NEUBAUER, Hans , FEHM, Tanja , SOLOMAYER, Erich , WALLWIENER, Diethelm , SOTLAR, Karl
发明人： BONIN, Michael , HOFFMANN, Jessica , WALTER, Michael , RIESS, Olaf , NEUBAUER, Hans , FEHM, Tanja , SOLOMAYER, Erich , WALLWIENER, Diethelm , SOTLAR, Karl
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6886 , C12Q2600/106 , C12Q2600/142 , C12Q2600/158
摘要： Die vorliegende Erfindung betrifft ein Verfahren zur Klassifizierung eines Patienten als platinsensitiv oder platinresistent, die Verwendung des Expressionsprofils einer Untergruppe von Genen zur Klassifizierung eines Patienten als platinsensitiv oder platinresistent sowie ein Verfahren zur Identifizierung von informativen Genen, um einen Patienten als platinsensitiv oder platinresistent klassifizieren zu können.
摘要翻译：
本发明涉及一种用于患者为铂敏感和铂抗性进行分类，使用基因的一个子集的表达谱的用于患者作为分类铂 - 敏感的和抗性铂以及用于识别信息的基因所涉及的方法将患者分类为铂敏感或铂耐药。

5. 发明公开

EP1938103A1 PHOSPHORYLATED OR NON-PHOSPHORYLATED MPR AS DIAGNOSTIC MARKER OR THERAPEUTIC TARGET 审中-公开
标题翻译：磷酸二氢钾NIC OS TER TER TER TER TER EL EL EL EL EL EL EL EL EL EL EL EL EL EL EL EL EL EL EL EL EL
公开(公告)号：EP1938103A1
公开(公告)日：2008-07-02
申请号：EP06805876.7
申请日：2006-09-26
申请人： ProteoSys AG
发明人： CAHILL, Michael , SCHRATTENHOLZ, André , KUREK, Raffael , WALLWIENER, Diethelm , NEUBAUER, Hans , CLARE, Susan
IPC分类号： G01N33/574 , C07K14/72
CPC分类号： G01N33/743 , C07K14/721 , G01N33/564 , G01N33/57407 , G01N33/57415 , G01N33/57434 , G01N33/57484 , G01N33/6893 , G01N2333/723 , G01N2500/00 , G01N2800/12 , G01N2800/28 , G01N2800/367
摘要： The invention relates to the use of phosphorylated and/or non- phosphorylated membrane associated progesterone receptor component 1 (mPR or PGRMC 1 ) or progesterone membrane component 2 (PGRMC2), in particular of at least one isoform thereof, and to other proteins, in particular isoforms thereof, as diagnostic markers and/or therapeutic targets for diseases associated with aberrant biological phenotypes, reagents for influencing mPR and/or the abundance and/or activity of said other proteins and to the use of an appropriate assay.
摘要翻译：本发明涉及使用磷酸化和/或非磷酸化的膜相关孕激素受体组分1（mPR），特别是其至少一种同种型，以及其它蛋白质，特别是其同种型作为诊断标记物和/或治疗剂与异常生物表型相关的疾病的靶标，影响mPR的试剂和/或所述其它蛋白质的丰度和/或活性以及使用适当的测定法。

6. 发明公开

EP2067040A2 USE OF AT LEAST ONE ISOFORM OF PROGESTERONE RECEPTOR MEMBRANE COMPONENT 1 (PGRMC1) 审中-公开
标题翻译：使用孕酮受体膜成分1的至少一种同种型（PGRMC1）
公开(公告)号：EP2067040A2
公开(公告)日：2009-06-10
申请号：EP07818454.6
申请日：2007-09-26
申请人： ProteoSys AG
发明人： CAHILL, Michael , NEUBAUER, Hans
IPC分类号： G01N33/574 , A61K38/00
CPC分类号： A61K38/1796 , A61K38/00 , C07K14/721 , G01N33/57415 , G01N33/57434 , G01N33/57492 , G01N33/6893 , G01N33/6896 , G01N33/74 , G01N2333/723 , G01N2800/102 , G01N2800/12 , G01N2800/24 , G01N2800/28 , G01N2800/2814 , G01N2800/32 , G01N2800/323 , G01N2800/367
摘要： The invention relates to the use of at least one isoform of progesterone receptor membrane component 1 (PGRMC1 ) as diagnostic marker and/or therapeutic target for diseases associated with neogenin and/or DCC and/or for the manufacture of a medicament for treatment of diseases associated with neogenin and/or DCC, the use of at least one reagent that influences the function of at least one isoform of PGRMC1 for the manufacture of a medicament for treatment of diseases associated with neogenin and/or DCC, the use of at least one isoform of PGRMC1 for influencing abundance or subcellular localisation of at least one class of molecules interacting with PGRMC1, an assay kit for diagnosis and/or therapy of diseases associated with neogenin and/or DCC, comprising at least one isoform of PGRMC1 and/or at least one reagent that influences the function of at least one isoform of PGRMC1, the use of at least one isoform of PGRMC1 as diagnostic marker in diagnosis for diseases associated with aberrant biological phenotypes, wherein the phosphorylation status of the at least one isoform of PGRMC1 is determined/and or estimated and the use of at least one reagent for influencing the abundance and/or activity of isoforms of proteins for diagnosis and/or therapy of diseases associated with aberrant biological phenotypes, wherein said proteins are involved in protein interaction or multiprotein complexes with either at least one isoform of phosphorylated or non-phosphorylated PGRMC1.

7. 发明公开

EP1789804A2 BREAST CANCER PROTEINS 审中-公开
标题翻译：乳房癌蛋白
公开(公告)号：EP1789804A2
公开(公告)日：2007-05-30
申请号：EP05791156.2
申请日：2005-09-14
申请人： ProteoSys AG
发明人： CAHILL, Michael , SCHRATTENHOLZ, André , KUREK, Raffael , WALLWIENER, Diethelm , NEUBAUER, Hans , CLARE, Susan
IPC分类号： G01N33/68
CPC分类号： G01N33/57415
摘要： The present invention relates to a pooling method for performing proteomics with human samples, preferably derived from microdissected human samples, wherein the samples are grouped into two or more pools and each pool reveals at least one protein that is differentially manifest between these pools but common to a member of a given pool. Besides, the invention refers to proteins whose abundances are upregulated in cancer cells, especially in breast cancer cells, preferably in breast cancer cells that are positive or negative towards hormone binding receptors.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式